Skip to Content
Patient-Derived Models Repository (PDMR)
Last Updated: 06/07/17

PDMR Database

Click here to access the PDMR Database.

PDMR Model Naming Structure

The NCI PDMR naming structure was developed to track each enrolled patient with a unique 6-digit randomized identifier and each collected specimen with a 3-digit collection code and letter indicating the type of tissue collected (e.g., 18-guage tissue biopsy = “T,” resected material = “R”). This combination (123456-000-R) gives a unique identifier to every specimen collected from enrolled patients and is used to create the unique distribution lot identifier.

PDXs (samples) are generally serial passaged subcutaneously, and the lineage can be tracked using the host-mouse identifier (an alphanumeric 3-digit identifier). The PDMR defines passage 0 (P0) as the first mouse passage implanted with the original human specimen. So, a P2 PDX would have a total of 9 digits if it was serially passaged (A12BC3D4E). If a PDX was generated through an alternate implant site, not subcutaneous, the letters “AL” will appear in the PDX name, and a note will be listed in the Specimen Notes defining the alternate implant location. If a PDX was generated from regrowth from a viably cryo-preserved fragment, the letters “RG” will appear in the PDX name. For instance, A12BC3_RG-D4E would indicate that the P2 tumor was generated from a regrowth of a cryopreserved fragment from the P1 tumor A12BC3. A sample labeled “Originator” represents the provided patient material and will at the minimum include pathological assessment. If there was sufficient tissue, sequence data will also be available.

There are some exceptions to these rules as early in the PDMR development we did not truly appreciate the complexity that would result. In those cases, alternate implant sites such as mammary fat pad or thigh muscle are noted in the Specimen Notes section, but may not be represented in the PDX name.

Types of Data Available

Patient
  • Diagnosis by CTEP SDC Code (sub-set of MEDdra disease codes)
  • Diagnosis sub-type
  • Gender
  • Date of Diagnosis (MM/YYYY only)
  • Age at Diagnosis
  • Known Metastatic Sites
  • Limited Medical Information
    • Current and Prior Therapies
    • Known Genetic Mutations and Tumor Markers of Patient
    • Additional Medical History, if Provided
  • Social History
    • Race/Ethnicity
    • Occupation
    • Smoking History
  • Specimens Collected for PDMR
Patient Specimen Information
  • Collection Procedure (e.g., biopsy, resection)
  • Biopsy/Resection Site
  • Date and Age at Collection
  • Summary of IDEXX Results for Human Pathogens
  • Specimen Notes: may include PDX IHC/Pathology findings of interest for model or alternate implant methodologies (if not subcutaneous)
  • Distribution Lot Availability
  • Representative PDX Growth Curve by Passage (Median Tumor Volume)
Sample

Samples include representative individual PDXs from a model and when available, originating patient material for the provided specimen

  • Passage number (P0 represented first implant)
  • PDM Type (e.g., PDX, Originator)
  • Pathology Data including 4x and 20x images, percent observed tumor content, percent necrosis, percent stromal component, and brief pathology write-up
  • List of available Sequence files including Whole Exome and RNASeq. Affymetrix data are currently not available
  • Detailed List of Variant Calls Using NCI’s Cancer Gene Panel (currently 62 genes based on NCI MPACT Clinical Protocol)
In Development
  • Consensus Genomic Variants: list of variants that are 100% represented in PDX whole exome sequencing data
  • Germline Whole Exome Sequence
  • Ancestry SNP Assessment
  • Whole Mouse Imaging (e.g., MRI, US)
  • Designation of Metastatic PDX Models
  • Preclinical Drug Study Results
  • In vitro Early-Passage Tumor and Cancer-Associated Fibroblast Cultures